A5068050082- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Chronic Lymphocytic Leukemia Research
- Immunotherapy and Immune Responses
- Chronic Myeloid Leukemia Treatments
- CAR-T cell therapy research
- Multiple Myeloma Research and Treatments
- Acute Lymphoblastic Leukemia research
- Polyomavirus and related diseases
- Renal Transplantation Outcomes and Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Lymphoma Diagnosis and Treatment
- Cytomegalovirus and herpesvirus research
- Immunodeficiency and Autoimmune Disorders
- Transplantation: Methods and Outcomes
- Monoclonal and Polyclonal Antibodies Research
- Cancer Immunotherapy and Biomarkers
- Mesenchymal stem cell research
- Neutropenia and Cancer Infections
- Protein Degradation and Inhibitors
- Virus-based gene therapy research
- Childhood Cancer Survivors' Quality of Life
Harvard University
2016-2025
Dana-Farber Cancer Institute
2016-2025
Boston University
1996-2025
Brigham and Women's Hospital
2014-2024
Dana-Farber Brigham Cancer Center
2011-2023
Regeneron (United States)
2023
Roche (Switzerland)
2023
St James's University Hospital
2020
Jena University Hospital
2020
Emmes (United States)
2020
Dysfunction of regulatory T (Treg) cells has been detected in diverse inflammatory disorders, including chronic graft-versus-host disease (GVHD). Interleukin-2 is critical for Treg cell growth, survival, and activity. We hypothesized that low-dose interleukin-2 could preferentially enhance vivo suppress clinical manifestations GVHD.
A large number of cancer-associated gene products evoke immune recognition, but host reactions rarely impede disease progression. The weak immunogenicity nascent tumors contributes to this failure in defense. Therapeutic vaccines that enhance dendritic cell presentation cancer antigens increase specific cellular and humoral responses, thereby effectuating tumor destruction some cases. attenuation T activation by cytotoxic lymphocyte-associated antigen 4 (CTLA-4) further limits the potency...
We conducted a Phase I clinical trial investigating the biologic activity of vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte–macrophage colony-stimulating factor in patients metastatic melanoma. Immunization sites were intensely infiltrated T lymphocytes, dendritic cells, macrophages, and eosinophils all 21 evaluable patients. Although lesions resected before minimally immune system patients, after densely lymphocytes plasma showed extensive...
Loss of donor-mediated immune antitumor activity after allogeneic hematopoietic stem-cell transplantation (HSCT) permits relapse hematologic cancers. We hypothesized that checkpoint blockade established by targeting cytotoxic T-lymphocyte–associated protein 4 with ipilimumab could restore reactivity through a graft-versus-tumor effect.
Regulatory T cell homeostasis is restored in patients with chronic graft-versus-host disease who receive low-dose interleukin-2 therapy.
Purpose Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition characterized by somatic mutations in the blood otherwise healthy adults. We hypothesized that patients undergoing autologous stem-cell transplantation (ASCT) for lymphoma, CHIP at time ASCT would be associated with increased risk myelodysplastic syndrome and acute myeloid leukemia, collectively termed therapy-related neoplasm (TMN), other adverse outcomes. Methods performed whole-exome sequencing on...
Background: It is unknown whether the reduction in HIV-1 reservoirs seen after allogeneic hematopoietic stem cell transplantation (HSCT) with susceptible donor cells sufficient to achieve sustained remission. Objective: To characterize blood and tissues perform analytic antiretroviral treatment interruptions determine potential for HSCT lead sustained, antiretroviral-free Design: Case report characterization of immunity before interruption. Setting: Tertiary care center. Patients: Two men...
Recurrently mutated genes in myelodysplastic syndrome (MDS) are pathogenic drivers and powerfully associated with clinical phenotype prognosis. Whether these types of mutations predict outcome after allogeneic hematopoietic stem-cell transplantation (HSCT) patients MDS is not known.We used massively parallel sequencing to examine tumor samples collected from 87 before HSCT for coding 40 recurrently genes.Mutations were identified 92% patients, most frequently the ASXL1 (29%), TP53 (21%),...
Umbilical cord blood (UBC) stem cells are a useful cell source for patients without matched related or unrelated donors. Adult transplantation with single UBC units is associated high transplantation-related mortality (TRM). In most cases, due to infection slow engraftment and immunoincompetence. this study, we used reduced-intensity conditioning regimen of fludarabine, melphalan, antithymocyte globulin followed by 2 partially units. The were 4/6 HLA match better each other the patient...